Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery

Inclusion Criteria: * Male or female, aged \>18 years. * Plan to undergo lipiodol TACE for HCC or NET liver metastases * Bilobar disease or distribution for which staged therapy (more than one TACE) for distinct target tumors is planned * Liver tumor burden does not exceed 50% of the liver volume * Patent main portal vein * Life expectancy of greater than 6 months * ECOG performance status 0-2 * Adequate liver function as measured by: Total bilirubin ≤ 2.0mg/dl, ALT, AST ≤5 times ULN, albumin ≥2.5g/dl * Adequate marrow and renal function as defined as: * Platelets \>75,000/mcL (may be corrected by transfusion) * Serum creatinine \< 2.0 mg/dl * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such contraception from beginning of study treatment until 1 month following last TACE treatment, as recommended for TACE treatments not conducted within the trial. * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner from first study treatment until 1 month following last TACE treatment. * Provision of signed and dated informed consent form and ability to consent for oneself. * Stated willingness to comply with all study procedures and availability for the study duration. Exclusion Criteria: * Absolute contraindication to contrast-enhanced MRI * Absolute contraindication to intravenous iodinated contrast, including history of previous severe contrast reaction or moderate reaction not mitigated by appropriate pre-medication * Pregnancy or lactation * Choledochoenteric anastomosis, transpapillary stent or sphincterotomy of duodenal papilla * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements